Price alert —
Sign in to get a one-time email the moment BEAM crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · BEAM
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $0.0B | $-0.1B | $-0.1B | $-0.1B | -297.2% | -337.8% |
| 2025-12-31 | $0.1B | $0.2B | $-0.0B | $-0.1B | 214.1% | -15.3% |
| 2025-09-30 | $0.0B | $-0.1B | $-0.1B | $-0.1B | -1162.4% | -1307.6% |
| 2025-06-30 | $0.0B | $-0.1B | $-0.1B | $-0.1B | -1208.3% | -1419.2% |
| 2025-03-31 | $0.0B | $-0.1B | $-0.1B | $-0.1B | -1450.2% | -1596.9% |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare BEAM vs peers
Line BEAM up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with BEAM
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-07 | -0.91 | -1.01 | +10.1% | +2.7% |
| 2026-02-24 | 2.33 | -1.12 | +309.0% | -8.3% |
| 2025-11-04 | -1.10 | -1.01 | -8.9% | +1.4% |
| 2025-08-05 | -1.00 | -1.09 | +8.4% | -2.1% |
| 2025-05-06 | -1.24 | -1.17 | -5.9% | +1.5% |
| 2025-02-25 | -1.09 | -1.22 | +10.3% | -6.5% |
| 2024-11-05 | -1.17 | -1.18 | +0.9% | +11.2% |
| 2024-08-06 | -1.11 | -1.12 | +0.7% | -4.2% |
| 2024-05-07 | -1.21 | -1.39 | +12.9% | -1.3% |
| 2024-02-27 | 1.73 | -0.71 | +343.6% | -3.2% |
| 2023-11-08 | -1.22 | -1.27 | +3.7% | -3.0% |
| 2023-08-08 | -1.08 | -1.38 | +21.6% | -0.5% |
| 2023-05-10 | -1.33 | -1.30 | -2.0% | -1.9% |
| 2023-02-28 | -0.54 | -1.34 | +59.6% | -4.3% |
| 2022-11-07 | -1.56 | -1.09 | -43.2% | +1.3% |
| 2022-08-09 | -1.02 | -1.02 | +0.4% | +7.8% |
| 2022-05-09 | -1.01 | -1.34 | +24.4% | +7.5% |
| 2022-02-28 | -0.95 | -0.94 | -1.1% | -6.2% |
| 2021-11-08 | -0.42 | -0.72 | +41.9% | -1.4% |
| 2021-08-10 | -1.23 | -0.74 | -66.8% | +3.6% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| BEAM ★ | $3B | — | -5.7 | 16.8 | -5.0 | 2.3 | -146.9% | 324.9% | — | -8.47% |
| LLY | $1,040B | 41.5 | 26.0 | — | 30.0 | 33.4 | 82.8% | 55.5% | 169.9% | 0.88% |
| UNH | $393B | 32.6 | 19.3 | 0.9 | 18.1 | 3.8 | 19.5% | 0.4% | 61.5% | 5.79% |
| JNJ | $615B | 29.7 | 19.9 | 6.3 | 18.3 | 7.6 | 68.1% | 6.6% | -1.0% | — |
| MRK | $316B | 36.0 | 13.3 | — | 12.0 | 6.9 | 76.7% | 4.9% | — | 4.45% |
| ABBV | $452B | 124.7 | 15.7 | 7.2 | 17.2 | -67.9 | 72.0% | 12.4% | -46.2% | 4.61% |
| PFE | $142B | 19.1 | 8.8 | — | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.69% |
| TMO | $194B | 28.7 | 19.2 | — | 20.8 | 3.7 | 40.9% | 6.2% | 11.3% | 2.85% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 68.07%
| Holder | Shares | % out |
|---|---|---|
| FMR, LLC | 12,452,199 | 12.10% |
| ARK Investment Management, LLC | 12,133,433 | 11.79% |
| Farallon Capital Management LLC | 10,134,696 | 9.85% |
| Blackrock Inc. | 8,487,569 | 8.25% |
| State Street Corporation | 5,699,265 | 5.54% |
| Vanguard Portfolio Management LLC | 4,570,797 | 4.44% |
| Arch Venture Management, Llc | 4,540,132 | 4.41% |
| Vanguard Capital Management LLC | 4,377,374 | 4.25% |
| Sumitomo Mitsui Trust Group, Inc. | 3,825,585 | 3.72% |
| Amova Asset Management Americas Inc | 3,825,585 | 3.72% |
Insider activity · 90d
0 buys / 5 sells · ratio 0.0 · Finnhub
- Simon Amy SELL 102,363 @ $34.73
- Evans John M. M 205,804
- Evans John M. SELL 1,047,205 @ $34.84
- Evans John M. SELL 1,049,105 @ $34.26
- Evans John M. M 1,072,205 @ $1.03
- Evans John M. M 230,804
- Evans John M. M 9
- Evans John M. SELL 1,047,205 @ $35.91
- Evans John M. SELL 1,058,784 @ $35.13
- Evans John M. M 1,072,205 @ $1.03
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-07-02 | 4 | view · |
| 4 | 2026-07-01 | 4 | view · |
| 4 | 2026-06-29 | 4 | view · |
| 4 | 2026-06-22 | 4 | view · |
| 8-K | 2026-06-08 | 8-K | view · |
| 4 | 2026-06-05 | 4 | view · |
| 4 | 2026-06-05 | 4 | view · |
| 4 | 2026-06-05 | 4 | view · |
| 4 | 2026-06-05 | 4 | view · |
| 4 | 2026-06-05 | 4 | view · |
| 4 | 2026-06-05 | 4 | view · |
| 10-Q | 2026-05-07 | 10-Q | view · |
| 8-K | 2026-05-07 | 8-K | view · |
| DEF 14A | 2026-04-17 | DEF 14A | view · |
| 4 | 2026-04-06 | 4 | view · |
| 4 | 2026-04-06 | 4 | view · |
| 4 | 2026-04-06 | 4 | view · |
| 4 | 2026-04-06 | 4 | view · |
| 4 | 2026-04-06 | 4 | view · |
| 4 | 2026-04-02 | 4 | view · |
| 4 | 2026-04-02 | 4 | view · |
| 4 | 2026-04-02 | 4 | view · |
| 4 | 2026-04-02 | 4 | view · |
| 4 | 2026-04-02 | 4 | view · |
| 4 | 2026-04-01 | 4 | view · |
| 8-K | 2026-03-05 | 8-K | view · |
| 4 | 2026-02-26 | 4 | view · |
| 10-K | 2026-02-24 | 10-K | view · |
| 8-K | 2026-02-24 | 8-K | view · |
| 8-K | 2026-02-12 | 8-K | view · |
| 8-K | 2026-02-05 | 8-K | view · |
| 4 | 2026-02-02 | 4 | view · |
| 4 | 2026-02-02 | 4 | view · |
| 4 | 2026-02-02 | 4 | view · |
| 4 | 2026-02-02 | 4 | view · |
| 4 | 2026-02-02 | 4 | view · |
| 4 | 2026-02-02 | 4 | view · |
| 4 | 2026-01-26 | 4 | view · |
| 4 | 2026-01-26 | 4 | view · |
| 4 | 2026-01-21 | 4 | view · |
| 4 | 2026-01-20 | 4 | view · |
| 8-K | 2026-01-12 | 8-K | view · |
| 4 | 2026-01-05 | 4 | view · |
| 4 | 2026-01-05 | 4 | view · |
| 4 | 2026-01-05 | 4 | view · |
| 8-K | 2025-12-11 | 8-K | view · |
| 10-Q | 2025-11-04 | 10-Q | view · |
| 8-K | 2025-11-04 | 8-K | view · |
| 4 | 2025-10-29 | 4 | view · |
| 4 | 2025-10-08 | 4 | view · |
| 4 | 2025-10-03 | 4 | view · |
| 4 | 2025-10-03 | 4 | view · |
| 4 | 2025-10-03 | 4 | view · |
| 10-Q | 2025-08-05 | 10-Q | view · |
| 8-K | 2025-08-05 | 8-K | view · |
| 4 | 2025-08-01 | 4 | view · |
| 4 | 2025-07-03 | 4 | view · |
| 8-K | 2025-07-03 | 8-K | view · |
| 4 | 2025-06-06 | 4 | view · |
| 4 | 2025-06-06 | 4 | view · |
About BEAM
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatme…
Options picks · BEAM
ITM + OTM ideas from the latest scanLoading…
Congress trades · BEAM
STOCK Act disclosuresLoading…
SEC filings & insiders · BEAM
EDGAR · liveLoading…
Holders · BEAM
Institutions & insider activityLoading…